Every Form 4 that Establishment Labs Holdings Inc. (ESTA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ESTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ESTA filings page.
ESTABLISHMENT LABS HOLDINGS INC. (ESTA) reported an insider equity transaction by Chief Executive Officer and director Filippo Caldini. On 2026-08-20, 682 Common Shares were withheld by the company to cover tax withholding obligations arising from the vesting of previously granted restricted stock units. This was reported as a code F transaction (payment of tax liability by delivering or withholding securities), and Caldini’s directly held position after this withholding was 48,829 Common Shares.
Chacon Quiros Juan Jose reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros received a grant of 11,315 Common Shares as a stock unit award under the company’s 2018 Equity Incentive Plan, at a stated price of $0.0000 per share. One-fourth of the shares subject to the award vest on April 24, 2027 and on each one-year anniversary thereafter, contingent on continued service. Following this grant, he holds 56,508 Common Shares directly and 927,504 Common Shares indirectly through Sariel Group Ltd, where he has voting and dispositive power but disclaims beneficial ownership beyond his pecuniary interest.
ESTABLISHMENT LABS HOLDINGS INC. director Nicholas Sheridan Lewin received a grant of stock options covering 19,561 common shares at an exercise price of $66.28 per share, expiring on April 24, 2036. One-fourth of these options vest on April 24, 2027 and on each one-year anniversary thereafter, subject to continued service. Following the transactions, he held 1,079,960 common shares directly and 19,090 common shares indirectly through his spouse, plus the newly granted options.
Harris Taylor C. reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Harris Taylor C. received two equity awards in the form of stock units representing common shares. One grant covers 1,773 common shares, and another covers 1,949 common shares, both awarded at no cash cost as director compensation under the company’s 2018 Equity Incentive Plan.
The 1,773-share award vests in three equal annual installments on each yearly anniversary of the grant date, subject to continued service. The 1,949-share award vests in full on the earlier of June 24, 2027 or the day before the next annual stockholder meeting, also contingent on ongoing service.
Gillin Leslie reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Leslie Gillin received 196 common shares as a stock grant on June 30, 2026. The shares were elected in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy and issued under the 2018 Equity Incentive Plan, based on a closing price of $85.81 per share. Following this compensation-related award, Gillin directly holds 18,594 common shares.
Custin Ann reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Ann Custin received an equity grant of common shares as part of her board compensation. She was awarded 239 common shares, elected in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy. The shares were issued under the 2018 Equity Incentive Plan at a reference price of $85.81 per share, based on the closing price on the last trading day of the quarter. Following this grant, Custin directly holds 24,325 common shares of the company.
LEWIN NICHOLAS SHERIDAN reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Nicholas Sheridan Lewin received 291 common shares as a stock grant. These shares were elected in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy and were issued under the 2018 Equity Incentive Plan, using a reference price of $85.81 per share.
After this grant, Lewin directly holds 1,079,960 common shares. An additional 19,090 common shares are reported as indirectly owned and are held by his spouse.
SCHUTTER EDWARD J reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Edward J. Schutter received a grant of 216 common shares on June 30, 2026, valued using a price of $85.81 per share. These shares were elected in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy, bringing his direct holdings to 177,952 shares.
Slotkin Bryan reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Bryan Slotkin reported receiving 189 common shares as compensation. These shares were granted in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy, based on a closing share price of $85.81. Following this award, Slotkin directly holds 32,799 common shares.
Harris Taylor C. reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Harris Taylor C. reported two equity awards of stock units under the company’s 2018 Equity Incentive Plan. One award covers 1,281 stock units, vesting in three equal annual installments on each yearly anniversary of the grant date, subject to continued service. A separate award covers 1,949 stock units, vesting in full on the earlier of June 24, 2027 or the day prior to the company’s next annual meeting of stockholders, also subject to continued service. Following the first transaction, Taylor’s reported direct holdings in common shares were 3,230 shares, and following the second, 1,949 shares are reported in that line item.
JW Asset Management–affiliated funds sold Establishment Labs shares and fell below a 10% ownership threshold. JW Partners and JW Opportunities Fund sold a total of 90,533 common shares in open-market trades on May 26–28, 2026 at prices around $72–$74 per share. After these sales, the reporting group indirectly held 2,890,582 shares. The Form 4 states this transaction caused the reporting persons to cease being beneficial owners of more than 10% of Establishment Labs’ common stock, and it is described as their final Form 4 for this issuer. The advisor and related entities disclaim beneficial ownership beyond their indirect pecuniary interests.
Slotkin Bryan reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Bryan Slotkin received an award of 2,354 common share stock units as compensation. The units were granted at a stated price of $0.00 per share under the company’s 2018 Equity Incentive Plan.
The shares subject to this award vest in full on the earlier of May 22, 2027 or the day prior to the company’s next annual meeting of stockholders, as long as Slotkin continues as a service provider through that date. After this grant, he directly holds 32,610 common shares.
SCHUTTER EDWARD J reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Edward J. Schutter received an equity award of 2,354 common share units on May 22, 2026, at no cash cost to him. This grant was made under the company’s 2018 Equity Incentive Plan as part of his director compensation.
The stock units vest in full on the earlier of May 22, 2027 or the day before the company’s next annual stockholder meeting, as long as he continues as a service provider through that date. After this award, Schutter directly holds 177,736 common shares.
Custin Ann reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. reported that director Ann Custin received an award of 2,354 common share stock units as equity compensation. The award was granted at no cash cost and increases her direct holdings to 24,086 common shares. The units vest in full on the earlier of May 22, 2027 or the day prior to the company’s next annual meeting of stockholders, provided she continues as a service provider through that date.
LEWIN NICHOLAS SHERIDAN reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Nicholas Sheridan Lewin received an award of 2,354 common share units at no cost under the company’s 2018 Equity Incentive Plan. The units vest in full on the earlier of May 22, 2027 or the day before the next annual meeting, if he continues as a service provider.
Following this grant, he holds 1,079,669 common shares directly and 19,090 common shares indirectly through his spouse.
Gillin Leslie reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Leslie Gillin received an award of 2,354 common share stock units as compensation. The award was granted at no cash cost to her and is tied to continued board service. These units vest in full on the earlier of May 22, 2027 or the day prior to the company’s next annual meeting of stockholders, provided she remains a service provider through that date. Following this grant, she holds 18,398 common shares directly.
ESTABLISHMENT LABS HOLDINGS INC. saw affiliated investment funds managed by JW Asset Management report open-market sales of its Common Shares. On May 20, 2026, a total of 3,580 shares were sold at $70.56 per share, and on May 21, 2026, 16,999 shares were sold at $71.40 per share. Footnotes state these transactions reflect 15,350 shares sold by JW Partners, LP and 5,229 shares sold by JW Opportunities Fund, LLC. After these trades, the reporting group collectively reports holding 2,981,115 Common Shares indirectly. The Advisor, the General Partner and Jason G. Wild each disclaim beneficial ownership except to the extent of any indirect pecuniary interest.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros reported open-market sales of common shares executed on May 6, 2026 through entity Sariel Group Ltd, which holds the shares. The filing shows a total of 105,000 shares sold in two tranches under a pre-established Rule 10b5-1 trading plan, concluding that plan after all its shares were sold. Following these transactions, he continues to hold 45,193 common shares directly and 927,504 common shares indirectly through Sariel Group Ltd.
ESTABLISHMENT LABS HOLDINGS INC. had 60,000 Common Shares sold in an open-market transaction on May 6, 2026, by investment entities associated with JW Asset Management. The sale occurred at an average price of $75.625 per share and was executed indirectly through JW Partners, LP and JW Opportunities Fund, LLC.
After this sale, the reporting group collectively held 3,001,694 Common Shares indirectly. JW Asset Management, LLC, JW GP, LLC and Jason G. Wild each disclaim beneficial ownership of these securities except to the extent of any indirect pecuniary interest.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros reported open-market sales totaling 75,000 Common Shares, executed indirectly through Sariel Group Ltd, an entity in which he has a pecuniary interest and over whose shares he has voting and dispositive power.
The sales occurred on May 1 and May 4, 2026 at weighted average prices between about $70 and $71 per share, under a Rule 10b5-1 trading plan. Following these transactions, Sariel Group Ltd holds 1,032,504 Common Shares indirectly attributed to him, and he also holds 45,193 Common Shares directly.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros reported indirect open-market sales totaling 75,000 common shares over April 23–27. The trades, executed at prices in the mid‑$60s per share, were carried out under a disclosed Rule 10b5-1 trading plan.
The shares were sold by Sariel Group Ltd., over which Chacon Quiros has voting and dispositive power, while disclaiming beneficial ownership beyond his pecuniary interest. After these sales, indirect holdings stood at 1,107,504 common shares, and a separate direct position was 45,193 common shares as of April 23.
Establishment Labs Holdings Inc. director-related entity Sariel Group Ltd sold 37,500 Common Shares of ESTA on April 14, 2026 in an open‑market transaction at a weighted average price of $65.228 per share, within a range of $65.00 to $65.60, under a pre‑arranged Rule 10b5-1 trading plan.
Following the sale, Sariel Group Ltd held 1,182,504 Common Shares indirectly attributable to director Juan Jose Chacon Quiros, while he also held 45,193 Common Shares directly. He disclaims beneficial ownership of Sariel Group Ltd’s shares except to the extent of his pecuniary interest.
ESTABLISHMENT LABS HOLDINGS INC. director and Chief Executive Officer Filippo Caldini reported equity compensation awards. He received stock options for 24,879 common shares at an exercise price of $76.23 per share, expiring on February 18, 2036, and a separate grant of 14,266 common shares.
According to the grant terms, one-fourth of both the stock units and the option shares vest on February 18, 2027, with additional one-fourth portions vesting on each one-year anniversary after that date, as long as he continues as a service provider. Following the share grant, he directly holds 49,511 common shares.
ESTABLISHMENT LABS HOLDINGS INC. director Edward J. Schutter exercised a stock option to acquire additional equity in the company. He exercised options covering 36,780 common shares at an exercise price of $4.11 per share via a cash exercise. Following the transaction, he directly owns 175,382 common shares, and the exercised option position has been fully converted into stock. The option had a multi-year vesting schedule, with half the shares vesting in 2016 and the remainder vesting in equal annual installments thereafter.
ESTABLISHMENT LABS HOLDINGS INC. director Leslie Gillin received an equity grant of common shares as part of regular board compensation. She acquired 297 common shares on the transaction date instead of a quarterly cash retainer, with the share amount based on the $56.78 closing price.
The shares were issued under the company’s 2018 Equity Incentive Plan and increase her direct holdings to 16,044 common shares. This is a routine, compensation-related award rather than an open-market purchase or sale.
Slotkin Bryan reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Bryan Slotkin received an automatic grant of 286 common shares valued at $56.78 per share. These shares were taken in lieu of his quarterly cash retainer under the company’s Outside Director Compensation Policy and issued from the 2018 Equity Incentive Plan.
Following this award, Slotkin directly holds 30,256 common shares. This is a routine, compensation-related equity grant rather than an open‑market share purchase.
LEWIN NICHOLAS SHERIDAN reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Nicholas Sheridan Lewin received a grant of 440 common shares, elected in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy. The shares were issued under the 2018 Equity Incentive Plan at a value based on the closing price of $56.78 per share.
Following this compensation award, Lewin directly holds 1,077,315 common shares. An additional 19,090 common shares are held indirectly through his spouse, reflecting associated family holdings rather than an open-market trade.
SCHUTTER EDWARD J reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Edward J. Schutter received 330 common shares on March 31, 2026 as a share-based retainer. The shares were issued under the company’s 2018 Equity Incentive Plan instead of a quarterly cash retainer, based on the closing share price for the quarter’s last trading day.
After this grant, Schutter directly holds 138,602 common shares, so the award represents a small, routine addition to his existing stake rather than an open-market purchase or sale.
Custin Ann reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Custin Ann reported receiving a grant of 363 common shares. The shares were awarded in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy, based on a closing price of $56.78 per share.
After this equity award issued pursuant to the 2018 Equity Incentive Plan, Custin Ann directly holds a total of 21,732 common shares.
Establishment Labs Holdings Inc. director Juan Jose Chacón Quirós reported an indirect open-market sale of 3,575 common shares at a weighted average price of $60.075 per share. The shares were sold by Sariel Group Ltd. under a pre-arranged Rule 10b5-1 trading plan.
After the sale, indirect holdings reported for Sariel Group Ltd. totaled 1,220,004 common shares, and Chacón Quirós also reported 45,193 common shares held directly. He disclaims beneficial ownership of shares held by Sariel Group Ltd. except to the extent of his pecuniary interest.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros reported a mix of entity restructuring and open-market sales of Common Shares. A total of 179,240 shares moved from his direct holdings to Sariel Group Ltd. in an exempt transfer, leaving him with 45,193 shares held directly.
Through Sariel Group Ltd., an entity in which he is a shareholder with voting and dispositive power, 33,925 shares were sold in open-market transactions on March 23, 2026 at prices generally between $60.00 and $63.01 per share under a Rule 10b5-1 trading plan. Following these transactions, 1,225,292 shares are reported as held indirectly via Sariel Group Ltd.
ESTABLISHMENT LABS HOLDINGS INC. Chief Financial Officer Cassandra Harris received new equity awards as part of her compensation. She was granted stock options for 12,877 common shares at an exercise price of $74.60 per share and a separate grant of 7,372 common shares.
Both awards vest over four years. One-fourth of the stock units and one-fourth of the option shares will vest on March 9, 2027, with additional one-fourth increments vesting on each one-year anniversary thereafter, as long as she continues as a service provider. Following these awards, she holds 12,877 options and 7,372 common shares directly.
Establishment Labs Holdings Inc. reported that General Counsel and Chief Compliance Officer Samuel Ross Mansbach had 657 common shares withheld on March 6, 2026 to cover tax obligations tied to vesting restricted stock units. These shares were valued at $70.41 per share. After this tax-withholding disposition, he held 18,663 common shares directly.
Establishment Labs Holdings Inc. reported that its General Counsel and Chief Compliance Officer, Samuel Ross Mansbach, received equity awards on February 16, 2026. He was granted stock options for 7,131 shares at an exercise price of $0.00 and 4,082 common shares as stock units.
According to the award terms, one-fourth of the stock units and one-fourth of the option shares vest on February 16, 2027, with additional one-fourth portions vesting on each one-year anniversary thereafter. Vesting is conditioned on Mansbach continuing as a service provider through each applicable vesting date.
Establishment Labs Holdings Inc. director and Chief Executive Officer Filippo Caldini reported equity awards on February 18, 2026. He was granted 14,275 stock options with a right to buy shares at an exercise price of $0.00, along with 8,185 common shares as stock units under the 2018 Equity Incentive Plan.
According to the award terms, one-fourth of both the stock units and the option shares will vest on February 18, 2027, with the remaining portions vesting in equal annual installments on each one-year anniversary thereafter, provided he continues as a service provider through each vesting date.
Establishment Labs Holdings Inc. director Juan Jose Chacon Quiros reported new equity awards. On August 3, 2025, he received 10,285 common shares at a price of $0, increasing his directly held common shares to 224,433. These stock units were granted under the company’s 2018 Equity Incentive Plan and are tied to a post-employment agreement signed on that date and a consulting agreement effective June 1, 2025.
He was also granted a stock option for 14,906 common shares with an exercise price of $36.46, fully unexercised after the transaction. Both the stock units and the option vest in four equal annual installments starting on June 1, 2026, as long as he continues as a service provider. Separately, 1,078,264 common shares are held indirectly by Sariel Group Ltd, an entity where he has voting and dispositive power but for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Establishment Labs Holdings Inc. (ESTA) reported an insider transaction on a joint Form 4 by affiliates of JW Asset Management. On 11/10/2025, the group reported an open‑market sale of 11,000 common shares at a price of $67.07 per share. Following the transaction, the group reported 3,061,694 shares beneficially owned, held indirectly.
Footnotes state the sale comprised 8,205 shares by JW Partners, LP and 2,795 shares by JW Opportunities Fund, LLC, with standard disclaimers regarding indirect pecuniary interest.
Establishment Labs (ESTA) reported an insider transaction on a Form 4 by JW Asset Management, LLC and affiliated reporting persons. On 11/07/2025, the group sold 2,500 common shares in an open-market transaction at $65.09 per share (transaction code S). Following the sale, the reporting persons beneficially owned 3,072,694 shares, held indirectly.
Per the footnotes, the 2,500 shares reflect sales by two affiliated funds: 1,865 shares by JW Partners, LP and 635 shares by JW Opportunities Fund, LLC. The filing indicates the structure of control and advisory roles among JW Asset Management, LLC, JW GP, LLC, and Jason G. Wild, with beneficial ownership disclaimed except to the extent of any indirect pecuniary interest.
Establishment Labs Holdings (ESTA) reported an insider transaction on a Form 4 involving multiple reporting persons affiliated with JW Asset Management. On 11/06/2025, the group sold 7,591 Common Shares at a price of $65 per share, coded “S” for sale. Following the transaction, 3,075,194 shares were reported as beneficially owned in aggregate with indirect ownership noted.
Footnotes state the sale comprised 5,662 shares by JW Partners, LP and 1,929 shares by JW Opportunities Fund, LLC. The filing lists JW Asset Management, LLC, JW Partners, LP, JW Opportunities Fund, LLC, JW GP, LLC, and Jason G. Wild as reporting persons, with customary beneficial ownership disclaimers. The form indicates it was filed by more than one reporting person.
Edward J. Schutter, a director of Establishment Labs Holdings Inc. (ESTA), received 457 common shares as payment in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy. The shares were issued under the Issuer’s 2018 Equity Incentive Plan and were valued based on the closing market price used to determine the share equivalent. After this issuance the reporting person beneficially owns 138,015 shares, held directly.
Establishment Labs Holdings Inc. (ESTA) director Ann Custin acquired 503 common shares on 09/30/2025 at a price of $40.99 per share. The shares were issued under the company’s 2018 Equity Incentive Plan and were elected in lieu of a quarterly cash retainer under the issuer’s Outside Director Compensation Policy; the number of shares was determined using the closing price on the last trading day of the quarter. Following the transaction, the reporting person beneficially owned 21,087 shares. The Form 4 was signed by the company’s CFO by power of attorney on 10/01/2025.
Establishment Labs Holdings director Nicholas Sheridan reported acquiring 609 common shares on 09/30/2025 at a price of $40.99 per share. These shares were issued under the company’s 2018 Equity Incentive Plan and represent shares elected to be received in lieu of a quarterly cash retainer under the issuer’s Outside Director Compensation Policy.
After the transaction the reporting person directly beneficially owned 1,076,532 shares. An additional 19,090 shares are noted as indirectly beneficially owned via the reporting person’s spouse. The Form 4 discloses this routine director compensation election and does not show derivative transactions.
Reporting person: Leslie Gillin, a director of Establishment Labs Holdings Inc. (ESTA), acquired common shares as director compensation.
Transaction details: On 09/30/2025 the reporting person received 411 common shares issued under the company's 2018 Equity Incentive Plan at an effective price of $40.99 per share, representing shares elected in lieu of a quarterly cash retainer. Following the issuance the reporting person beneficially owned 15,516 common shares directly. The transaction was reported on Form 4 and signed by power of attorney on 10/01/2025.